We encourage further longitudinal investigations into the clinical application of these biomarkers and studies to elucidate the variation of activin A, inhibin A and follistatin-related proteins in preeclampsia as a manifestation of a maternal disease or as markers of abnormal placentation. The gene discussed is FST; the disease is preeclampsia.